Singapore markets close in 4 hours 9 minutes
  • Straits Times Index

    3,205.65
    -12.52 (-0.39%)
     
  • Nikkei

    28,810.91
    -287.33 (-0.99%)
     
  • Hang Seng

    25,604.81
    -23.93 (-0.09%)
     
  • FTSE 100

    7,253.27
    -24.35 (-0.33%)
     
  • BTC-USD

    58,881.50
    -2,476.95 (-4.04%)
     
  • CMC Crypto 200

    1,411.05
    -63.28 (-4.29%)
     
  • S&P 500

    4,551.68
    -23.11 (-0.51%)
     
  • Dow

    35,490.69
    -266.19 (-0.74%)
     
  • Nasdaq

    15,235.84
    +0.12 (+0.00%)
     
  • Gold

    1,801.90
    +3.10 (+0.17%)
     
  • Crude Oil

    81.18
    -1.48 (-1.79%)
     
  • 10-Yr Bond

    1.5290
    -1.5290 (-100.00%)
     
  • FTSE Bursa Malaysia

    1,571.62
    -11.46 (-0.72%)
     
  • Jakarta Composite Index

    6,535.08
    -67.13 (-1.02%)
     
  • PSE Index

    7,150.51
    -79.64 (-1.10%)
     

Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Novavax NVAX announced that it has filed a regulatory application to the World Health Organization (“WHO”) for the emergency use listing of its COVID-19 vaccine, NVX-CoV2373.

The listing, if allowed, will enable the company to supply its COVID-19 vaccine to nations participating in the COVAX facility. The COVAX facility aims to provide equitable access to COVID vaccines across low- and lower-middle-income countries.

The company has partnered with Serum Institute of India (“SII”), the world’s largest vaccine producer, to jointly supply 1.1 billion doses of NVX-CoV2373 to countries participating through the COVAX facility.

Both Novavax and SII have already completed the submission of regulatory filings for Emergency Use Authorization (“EUA”) of NVX-CoV2373 in India, Indonesia, and the Philippines. The submission to WHO is based on the regulatory submission made to the Indian health regulator.

Novavax’s shares increased 10.9% on Sep 23, following the above news. In fact, the stock has rallied 130.7% so far this year in comparison with the industry’s 0.7% increase.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Data from the phase III PREVENT-19 study, which evaluated NVX-CoV2373 in the United States and Mexico, were announced in June. The study met its primary endpoint by demonstrating an overall vaccine efficacy of 90.4%. The vaccine also provided 100% protection against moderate and severe coronavirus disease - a key secondary endpoint.

The company is also evaluating NVX-CoV2373 in another phase III study in the United Kingdom. Data from the study has demonstrated that the vaccine achieved an overall efficacy of 89.7%. It also provided an efficacy of 96.4% against the original COVID-19 strain and 86.3% against the Alpha variant of the virus.

Currently, the WHO has granted EUL to the COVID vaccines developed by AstraZeneca AZN, Moderna MRNA and Pfizer PFE/BioNTech that supplied millions of doses to the world. Earlier this week, Pfizer/BioNTech announced plans to provide the U.S. government with 500 million additional doses of their COVID vaccine at a not-for-profit price for donation to members of COVAX and the African Union.

Although Novavax is yet to file regulatory applications in the United States for its COVID vaccine, NVX-CoV2373 holds strong potential as there is a requirement for several billion doses across the world. The company plans to apply to the FDA for EUA for NVX-CoV2373 in fourth-quarter 2021.

Novavax, Inc. Price

Novavax, Inc. Price
Novavax, Inc. Price

Novavax, Inc. price | Novavax, Inc. Quote

Zacks Rank

Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Moderna, Inc. (MRNA) : Free Stock Analysis Report

Novavax, Inc. (NVAX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting